Navigation Links
Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
Date:5/2/2013

RICHMOND, Calif., May 2, 2013 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in new proprietary bi-functional metal-chelation technology for use in targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4® bi-functional chelator technology and has extended the collaboration to include additional chelator families.  These technologies are currently being developed by Algeta to conjugate thorium-227 to tumor-targeting molecules to create Targeted Thorium Conjugates (TTCs).Lumiphore's Lumi4® technology is based on a unique class of bi-functional metal chelators1 that forms a cage structure surrounding and tightly binding thorium-227, which can then be covalently attached to a range of tumor-targeting molecules, such as monoclonal antibodies, to create cancer therapeutics.  These bi-functional chelators provide a critical component enabling payload delivery for radio-therapeutic agents.  Algeta originally signed an option/license agreement with Lumiphore around this technology in 2010 and subsequently extended it to enable further evaluation to be conducted.  This stage of evaluation has now been completed successfully.

In parallel with this license agreement, Algeta has also been granted a license by Lumiphore covering a second class of bi-functional chelators that bind strongly to thorium-227, with the option of including a further selection of compounds within that license, if future exploratory work confirms their promise.  Under the agreements, Algeta has the future potential to develop in vivo companion diagnostics for radio-imaging.

"Lumiphore's goal is to bring the benefits of bi-functional metal-chelation technology, through a variety of synthetic designs, to therapeutic markets that use targeted radiopharmaceuticals to treat cancer by the tumoricidal action of the radionuclide micro-irradiation.  The ability to chelate radioactive metal isotopes (radiotracers) and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond , President and CEO of Lumiphore.  "Our technology also offers another therapeutic modality for those using antibody-drug conjugates," explained Steve Blose , Lumiphore's Chief Business Officer. He further explained that pharmaceutical companies using therapeutic antibodies could incorporate Lumiphore's technology to develop site-directed in vivo radiodiagnostics to diagnose and monitor therapeutic efficacy through radio-imaging.

Thomas Ramdahl, Algeta's Chief Technology Officer, said: "Algeta is assembling a broad portfolio of proprietary technologies (including bi-functional chelators, linkers and tumor-targeting molecules), intellectual property and expertise as a platform for generating Target Thorium Conjugates, or TTCs.  The addition of the Lumiphore technologies to the portfolio through this license and further option agreements will ensure that we have access to the best bi-functional chelators for thorium-227 as we seek to create a pipeline of TTCs designed to address multiple high-value opportunities in targeted cancer therapy."

About Lumiphore, Inc.Based in Richmond, California, Lumiphore, Inc., a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide and chelation technology for use in high-value imaging and therapeutic applications which are commercialized through market-specific alliances with corporate partners.  Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond , a world expert on lanthanide and actinide chemistry.  For more information please visit www.lumiphore.com. Lumi4® is a registered mark of Lumiphore, Inc.

About AlgetaAlgeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.  The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA).  For more information please visit www.algeta.com.

MEDIA CONTACTSFor Lumiphore, Inc.Kenneth N. Raymond, Ph.D.

President and Chairman

Tel./FAX: +510-232-8455

kraymond@lumiphore.comFor Algeta ASAMike Booth / Renate Birkeli

+47 23 00 67 32Communications & Corporate Affairs

ir@algeta.comMedia enquiries:Mark Swallow

+44 207 638 9571Citigate Dewe Rogerson

mark.swallow@citigatedr.co.ukKnut Ekern

+47 22 04 82 00Gambit Hill & Knowlton

knut.ekern@hkstrategies.com Kari Watson

+1 781 235 3060MacDougall Biomedical Communications

kwatson@macbiocom.com 1 Known as aromatic macrocyclic bi-functional chelators (AMBFs): one end binds the radionuclide/radiotracer (thorium-227) and the other end links to the tumor-targeting molecule.


'/>"/>
SOURCE Lumiphore, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... Getting enough sleep affects much more than energy – it also has mental and physical ... compromise motor reaction time, which can increase the risk of having a car accident. ... from the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... California (PRWEB) , ... April 28, 2017 , ... ... T8 Direct Replace tubes . These lamps offer an instant energy-saving solution for ... need to rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
Breaking Medicine News(10 mins):